Wegovy 12.5 mg: Does This Dose Exist?

What the MHRA-approved dose schedule says

Wegovy (semaglutide) is a GLP-1 receptor agonist made by Novo Nordisk. Its UK licence, granted by the MHRA, sets out a specific titration pathway beginning at 0.25 mg once weekly. From there, the prescriber steps the dose upward through 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg, the standard maintenance dose evaluated in the STEP 1 trial published in the New England Journal of Medicine, which reported an average body-weight reduction of around 15% over 68 weeks. Each step takes roughly four weeks, and the timing is driven by tolerability as much as efficacy. Rushing it does not improve results; it mainly increases the chance of gastrointestinal side effects like nausea or vomiting.

In January 2026 the MHRA approved a 7.2 mg maintenance dose, initially supplied as three 2.4 mg pens per week, and then on 14 April 2026 as a dedicated single-dose 7.2 mg pen. Trials at this strength reported around 20.7% average weight loss over 72 weeks. That is the current ceiling. 12.5 mg has never featured in Wegovy's licensed schedule, its clinical trial programme, or any MHRA approval.

You can read more about how the full titration ladder is structured on the Wegovy doses overview.

Why people search for a 12.5 mg strength, and what that tells us about counterfeit risk

The number 12.5 mg does appear in a different GLP-1 context: tirzepatide (Mounjaro) has a 12.5 mg strength. It is plausible that some searches conflate the two, or that sellers marketing unlicensed products have borrowed the number to make listings look credible alongside Mounjaro results. Either way, a Wegovy product labelled 12.5 mg is not what it claims to be.

The MHRA has warned repeatedly about counterfeit weight-loss pens sold via social media and unverified online channels. In late 2025 approximately 20 million doses of illegally traded weight-loss medicines (worth around £45 million) were seized, and the first UK site manufacturing fake tirzepatide pens was raided. Fake pens have been found to contain entirely different substances, including insulin, with serious consequences for people who used them unknowingly. The safe approach is to purchase only through a pharmacy you can verify on the GPhC register. A quick check takes under a minute: search the pharmacy's name or premises registration number, and confirm the listing is current before handing over any payment or health information.

If you have already encountered a listing for Wegovy 12.5 mg, report it to the MHRA's Yellow Card scheme, which accepts reports about suspect sellers as well as side effects.

The highest licensed Wegovy dose: what 7.2 mg adds

For patients who tolerate 2.4 mg well and want to explore the highest available maintenance dose, 7.2 mg is the clinically authorised next step, not 12.5 mg, and not any figure above 7.2 mg. The MHRA approved the dedicated 7.2 mg single-dose pen on 14 April 2026 for adults with a BMI of 30 or above. It is not currently licensed for people with a BMI below that threshold or for the cardiovascular indication. Starting dose remains 0.25 mg; the path to 7.2 mg is built on the same four-weekly titration steps, and the prescriber decides whether a patient has reached an appropriate point to continue beyond 2.4 mg.

Results at 7.2 mg, around 20.7% average weight loss over 72 weeks, narrow the gap with tirzepatide 15 mg considerably, a comparison explored in more detail on the general Wegovy treatment page. Dose availability at any given time is confirmed during the clinical consultation, not in advance. The NHS's own patient-level guidance on semaglutide covers what to expect at each stage of treatment and when to contact a prescriber.

If you are trying to understand where the different maintenance-dose options fit within the broader treatment picture, the weight-loss treatment overview sets this in context alongside other licensed medicines. For questions specific to earlier dose steps, including details on Wegovy 2.5 and how it fits into the titration journey, the Wegovy dose guide covers each strength in turn. And if cost is part of your thinking, the guide to sourcing Wegovy safely in the UK sets out what a legitimate private prescription should and should not include.

Semaglutide is a prescription-only medicine. A prescriber assesses clinical suitability before any treatment begins, that includes reviewing your current dose, your health history and your goals. If you want to know more about the 2.5 Wegovy pen, including how it is used and what to expect, speak to our prescribers to understand which licensed dose is right for your situation.